Most of us know Vitamin D as the “sunshine vitamin” that helps keep bones strong. But new research shows it’s also critical for immunity, muscle function, and healthy aging. Despite this, an estimated 1-in-2 of the global population has sub-optimal Vitamin D levels. Modern indoor lifestyles, limited dietary sources, and seasonal changes mean many people never reach the levels their bodies need.
Why standard vitamin D takes time
The majority of supplements on the market provide Vitamin D3. After ingestion, your liver must convert D3 into calcifediol—the active form your body can circulate and use. This conversion takes time. In some cases, it can be months before blood Vitamin D levels reach the optimal range, leaving gaps in immunity and bone support.
The science behind ampli-D®
ampli-D® represents a shift in approach. Rather than supplying Vitamin D3 (the precursor), it delivers calcifediol directly, the same form your body naturally uses. Because it bypasses the liver’s conversion step, research shows ampli-D® can raise blood Vitamin D levels up to three times faster than standard D3 supplements at equivalent doses.
More than 15 human studies have examined calcifediol, showing that it reaches circulation quickly, is metabolically active, and supports cellular processes. From calcium absorption to immune system regulation, calcifediol acts more efficiently than traditional Vitamin D3.
Why faster vitamin D status matters
Reaching optimal Vitamin D levels more quickly can help:
-
Support immune defenses at times when the body is most vulnerable
-
Maintain bone and muscle function, reducing age-related loss
-
Support healthy aging, mobility, and recovery
A new benchmark for supplementation
In 2024, the European Commission approved calcifediol (ampli-D®) as a novel food, confirming its safety and allowing wider access. This marks an important step toward making next-generation Vitamin D solutions available to more people—not just to correct deficiencies but to maintain long-term health.
ampli-D® is a trademark of dsm-firmenich group.
